Abstract: Amides and esters of 2-(substituted sulfamyl)-6-nitro-benzoic acid, in which the substituents on the sulfamyl nitrogen are non-basic, such as: hydrogen, alkyl, hydroxyalkyl and non-basic heterocycles, which are useful as adjuncts to radiation therapy.
Abstract: 2-(Substituted sulfamyl) derivatives of 6-nitrobenzoic acid wherein at least one of the sulfamyl substituents is a basic substituent selected from amino-(lower alkyl), (lower alkyl)-amino-(lower alkyl), or di(lower alkyl)-amino-(lower alkyl) are disclosed to have activity in increasing the sensitivity of hypoxic tumor cells to therapeutic radiation. Also disclosed are methods of preparing such compounds and pharmaceutical compositions including such compounds.
Abstract: Novel nitropyrazinyl- and nitropyridinyl- substituted piperazin-3-one and hexahydro-1H-1,4-diazepin-5-one compounds are disclosed to have activity in increasing the sensitivity of hypoxic tumor cells to radiation. Also disclosed are methods of preparing such compounds and pharmaceutical compositions including such compounds.
Abstract: The subject disclosure discloses a chemical intermediate in antibiotic synthesis of the structure: ##STR1## wherein R.sub.1 is H or OH and the asterisks indicate asymmetric carbon atoms. Compounds of this type may be obtained by fermentation with a strain of B. subtilis under aerobic conditions. Compounds of the above structure are biologically inactive but are converted by phosphorylation of the hydroxyl group to produce compounds of the structure: ##STR2## wherein R.sub.1 is H or OH, which are useful antibacterial substances having a broad spectrum of antibacterial activity.
Type:
Grant
Filed:
February 4, 1985
Date of Patent:
September 2, 1986
Assignee:
Merck & Co., Inc.
Inventors:
Eugene D. Thorsett, Joanne M. Williamson, Kenneth E. Wilson
Abstract: 2,6-Disubstituted derivatives of 3-nitropyrazine are disclosed to have activity in increasing the sensitivity of tumor cells to radiation. Also disclosed are methods of preparing such compounds and pharmaceutical compositions including such compounds.
Abstract: Amide and ester derivatives of 2-[N-(morpholinoalkyl)aminosulfonyl]-6-nitrobenzoic acids are disclosed to have activity in increasing the sensitivity of hypoxic tumor cells to therapeutic radiation. Also disclosed are methods of preparing such compounds and pharmaceutical compositions including such compounds.
Abstract: The present application is concerned with compounds useful as carriers of cytotoxic agents. More particularly it deals with derivatives of steroid compounds having a 5-androstene carbon skeleton and having an oleyl ester at the 3-position and having a 17-carbamyl alkyl substituent which linked to cytotoxic agents for delivery to cancer cells exclusively via the low-density lipoprotein (LDL) pathway.
Abstract: Disclosed is a process for preparing antibiotic 1-oxadethiacephalosporins via diazo-species I: ##STR1## wherein: A is acyl; R.sup.1 is H or OCH.sub.3 ; and R.sup.2 is a protecting group.
Abstract: The invention disclosed herein relates to novel 1-deoxyglycosides, preferably 1-deoxy-D-mannopyranosides and 1-deoxy-L-rhamnopyranosides, having in the 1-position of the pyranose ring an aralkylthio/aralkenylthio, aralkyloxy/aralkenyloxy or aralkanoylamino/aralkenoylamino substituent; and to novel processes for preparing these 1-substituted-1-deoxyglycosides starting with the corresponding tetra-O-acetylglycopyranosyl bromide or amine. The 6-hydroxy group of 1-substituted-1 deoxyglycopyranosides can also be replaced by other functional groups. These aralkylthio/aralkenylthio, aralkyloxy/aralkenyloxy and aralkanoylamino/aralkenoylamino 1-deoxyglycosides are potent inhibitors of antigen-specific T-cell proliferation and are also useful as inhibitors of delayed-type hypersensitivity reactions.
Type:
Grant
Filed:
October 11, 1983
Date of Patent:
November 19, 1985
Assignee:
Merck & Co., Inc.
Inventors:
Mitree M. Ponpipom, Tsung-Ying Shen, Robert L. Bugianesi
Abstract: Difficidin and derivative antibacterial compounds of the formula: ##STR1## where R.sub.a and R.sub.b are members independently selected from the group consisting of hydrogen; alkali metal and alkaline earth metal cations; ammonium; and substituted ammonium; and R.sup.1 is hydrogen or hydroxy.
Type:
Grant
Filed:
June 13, 1983
Date of Patent:
October 8, 1985
Assignee:
Merck & Co., Inc.
Inventors:
Sheldon B. Zimmerman, Kenneth E. Wilson, Richard L. Monaghan, Sagrario M. Del Val, Maria I. M. Fernandez, Otto D. Hensens, James E. Flor, Cheryl Deriso
Abstract: Disclosed is a chiral, total synthesis of thienamycin from D-glucose which proceeds via intermediates I, II and III to known aldehyde IV which is known to be useful in the total synthesis of thienamycin (V): ##STR1## wherein: R is lower alkyl having 1-6 carbon atoms or bi-valent alkyl having 2-6 carbon atoms which joins the two sulfur atoms; R.sup.1 is lower alkyl or aralkyl, such as benzyl and the like; and R.sup.2 is hydrogen or a removable protecting group, such as triorganosilyl wherein the organo groups are independently selected from lower alkyl, phenyl and phenylloweralkyl.
Abstract: Disclosed is the antibiotic 6-(1-hydroxyethyl)-2-substituted-thio-3-tetrazolyl-1-carbadethiapen-2-em and its pharmaceutically acceptable salts (I): ##STR1## wherein Z is C.sub.1 -C.sub.3 alkylamino, C.sub.1 -C.sub.3 alkylguanidino, C.sub.1 -C.sub.3 alkylamidino, or heterocycloalkyl and, M=H, a synthetically useful cation, or pharmaceutically acceptable cation. Such compounds as well as their pharmaceutically acceptable salts are useful as antibiotics. Also disclosed are processes for the preparation of such compounds; novel intermediates; pharmaceutical compositions comprising such compounds; and methods of treatment comprising administering such compounds and compositions when an antibiotic effect is indicated.
Type:
Grant
Filed:
October 5, 1983
Date of Patent:
October 1, 1985
Assignee:
Merck & Co., Inc.
Inventors:
W. Alexander Andrus, Burton G. Christensen, James V. Heck
Abstract: A novel synthon useful in the conversion of penicillin is a compound of the formula ##STR1## wherein R.sub.3 is a number of the group consisting of trimethyl-silyl, t-butyl dimethyl silyl, trimethyl silyl, methyl, benzyl or nitrobenzyl, and R.sub.5 is the same or different member of the group R.sub.3 is prepared by the naphthalene sulfonyl azide exchange reaction with benzyl acetoacetate, p-nitrobenzylacetoacetate, or methylacetoacetate to obtain the corresponding 2-diazo compound which is then silylated in hexamethyl-disalazine.
Type:
Grant
Filed:
January 23, 1984
Date of Patent:
June 25, 1985
Assignee:
Merck & Co., Inc.
Inventors:
Joseph S. Amato, Sandor Karady, Leonard M. Weinstock
Abstract: This invention relates to a new class of penicillins (I) and their pharmaceutically acceptable salts and esters which are useful as antibiotics: ##STR1## wherein the stylized radical (hereafter referred to as R'): ##STR2## attached to the 6-amino nitrogen moiety of the penicillin (or ring analogue thereof) nucleus represents a mono- or polycyclic N-containing heterocyclic group;X is S, SO, CH.sub.2, or O; m is 0, 1 or 2;R is, inter alia, hydrogen, substituted and unsubstituted: alkyl, aryl, alkenyl, heterocyclylalkyl, heterocyclylalkenyl, aralkenyl, aralkyl, --NR.sub.2, COOR, CONR.sub.2, --OR, or CN;R.sup.2 is H, or lower alkoxyl.
Abstract: Disclosed is a process for the stereocontrolled total synthesis of thienamycin, which synthesis proceeds via intermediate II: ##STR1## wherein R.sup.5 and R.sup.6 are removable protecting groups.
Abstract: Novel peptides of the formula: ##STR1## where A through G, X and Y are various amino acids and substituents; having long lasting LHRH agonist and antagonist activity; useful in promoting fertility, reducing fertility, respectively.
Abstract: Disclosed is a chiral, total synthesis of thienamycin from D-glucose which proceeds via intermediates I, II, III and IV to known lactone V which is known to be useful via acid VI in the total synthesis of thienamycin (VII): ##STR1## wherein R.sup.1 is hydrogen or a removable protecting group; R is a removable protecting group.
Abstract: The (5-R-2-oxo-1,3-dioxolen-4-yl)methyl moiety: ##STR1## wherein R is loweralkyl of 1-6 carbon atoms, especially methyl or t-butyl; when utilized as an ester on a pharmaceutical having a carboxylic acid functionality, enhances oral absorption of the pharmaceutical. This effect is applicable to a broad range of pharmaceutically active substances, including antibiotics, and antihypertensives as well as other classes of therapeutic agents.